Elvitegravir vs Raltegravir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Elvitegravir · Stribild
Marketed by Gilead Sciences and partners
NCT01095796 · Phase 3 · completed
Participants were randomized and quadruple-blinded to Stribild or active-controlled Atripla, with 348 and 352 treated participants analyzed, respectively. The primary week-48 virologic endpoint met the prespecified non-inferiority criterion, but HIV-1 RNA suppression is a surrogate endpoint rather than a hard clinical or endoscopic outcome.
Reported efficacy
The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1% (met)
Result source: NCT01095796
Raltegravir · Isentress
Marketed by Merck & Co.
NCT00293254 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 351 patients, using HIV-1 RNA suppression - a regulator-accepted, disease-defining measure - as the primary endpoint. The raltegravir arm showed clearly higher suppression rates than placebo at both Week 16 and Week 48, with confidence intervals that do not overlap, indicating a statistically robust and clinically meaningful benefit.
Next expected readout: January 2028 · NCT02140255 (registry estimate)
Reported efficacy
Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks); Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48 (48 Weeks); Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL (156 Weeks); Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL (240 Weeks): Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3) (met)
Result source: NCT00293254
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Elvitegravir | Raltegravir |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 87.6% vs 84.1%vs AtriplaNCT0109579634 other results
| —Not posted · NCT01195467 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Not posted · NCT01195467 |
| CD4 count, change (week 48) | 239 vs 206vs AtriplaNCT0109579626 other results
| 98.4 vs 39.8+58.6 vs placeboNCT002932546 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Elvitegravir
- 87.6% vs 84.1%vs AtriplaNCT01095796
34 other results
- 91.6% vs 88.5% NCT01797445
- 87.2% vs 80.8% NCT01705574
- 93.1% vs 92.8% NCT01780506
- 59% vs 57.8% NCT00708162
- 93.8% vs 87.1% NCT01475838
- 93.4% vs 88.1% NCT01495702
- 89.5% vs 86.8% NCT01106586
- 80.2% vs 75.3% NCT01095796
- 86.9% vs 83.1% NCT01780506
- 77.6% vs 74.6% NCT01106586
- 84.2% vs 81.5% NCT01095796
- 92.8% vs 89.1% NCT01815736
- 84% vs 82.3% NCT01797445
- 89.2% vs 88.2% NCT01780506
- 47.6% vs 45% NCT00708162
- 52.4% vs 53% NCT00708162
- 53.6% vs 56.4% NCT00708162
- 86.9% vs 69.8% NCT01475838
- 86.6% vs 80.4% NCT01495702
- 83.3% vs 82.3% NCT01106586
- 85.9% vs 83.2% NCT01095796
- 88.8% vs 85.5% NCT01095796
- 59.8% vs 57.5% NCT00708162
- 61% vs 60.7% NCT00708162
- 86.1% vs 84.8% NCT01106586
- 91.5% vs 88.5% NCT01106586
- 76.1% vs 78.1% NCT01095796
- 78.4% vs 73.1% NCT01106586
- 88.4% vs 89.7% NCT01497899
- 89.6% vs 87% NCT00869557
- 88.4% vs 87.9% NCT01497899
- 89.6% vs 87% NCT00869557
- 91.7% vs 82.6% NCT00869557
- 89.6% vs 87% NCT00869557
- Raltegravir
- —Not posted · NCT01195467
HIV-1 RNA 50 copies/mL or more (week 48)
- Elvitegravir
- —Not reported
- Raltegravir
- —Not posted · NCT01195467
CD4 count, change (week 48)
- Elvitegravir
- 239 vs 206vs AtriplaNCT01095796
26 other results
- 225 vs 200 NCT01797445
- 235 vs 221 NCT01780506
- 138 vs 147 NCT00708162
- 56 vs 58 NCT01495702
- 295 vs 273 NCT01095796
- 60 vs 42 NCT01815736
- 221 vs 212 NCT01705574
- 40 vs 32 NCT01475838
- 207 vs 211 NCT01106586
- 274 vs 260 NCT01797445
- 285 vs 271 NCT01780506
- 205 vs 198 NCT00708162
- 61 vs 71 NCT01475838
- 83 vs 101 NCT01495702
- 256 vs 261 NCT01106586
- 321 vs 300 NCT01095796
- 323 vs 310 NCT01780506
- 280 vs 293 NCT01106586
- 360 vs 328 NCT01095796
- 338 vs 340 NCT01106586
- 56 vs -1 NCT02616783
- 48 vs -4 NCT02616783
- 177 vs 204 NCT01497899
- 240 vs 166 NCT00869557
- 165 vs 179 NCT01497899
- 161 vs 117 NCT00869557
- Raltegravir
- 98.4 vs 39.8+58.6 vs placeboNCT00293254
6 other results
- 120.2 vs 49.4 NCT00293267
- 157.2 vs 54.2 NCT00293254
- 170.9 vs 71.0 NCT00293267
- 8.6 vs 21.9 NCT00772590
- 2.7 vs 21.9 NCT00772590
- 192 vs 205 NCT00762892
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Elvitegravir: 8 of 8 rows · Raltegravir: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Elvitegravir Rows use multiple source trials | Raltegravir Rows use multiple source trials |
|---|---|---|
| CD4+ absolute change · cells/uL Extension (open-label) | 265 vs 35 GEN cells/uLa,b,c NCT01705574 · Phase 3 · registry result, not featured evidence | 172.1 vs 54.1 placebo cells/uL @ 240wk400 mg b.i.d.a,b,c NCT00293254 · Phase 3 · combination 1 other source trial193.6 vs 68.2 placebo cells/uL @ 240wk400 mg b.i.d NCT00293267 · Phase 3 · combination |
| CD4+ absolute change · cells/uL No placebo or comparator arm | 229 cells/uL @ 48wkd,a,b NCT01721109 · Phase 2/3 · registry result, not featured evidence | 232 cells/uL @ 48wkd,a,b NCT02131233 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA LT 40 Copies responder rate · % of participants No placebo or comparator arm | 93.3% (n=223)e,a,b NCT02397096 · Phase 3 · registry result, not featured evidence show 3 more doses93.3% (n=223) @ 24wk NCT02397096 · Phase 3 · registry result, not featured evidence 89.7% (n=447) NCT02397096 · Phase 3 · registry result, not featured evidence 92.8% (n=447) @ 24wk NCT02397096 · Phase 3 · registry result, not featured evidence | 81.5% (n=531) @ 96wka,b NCT02131233 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA LT 50 Copies responder rate · % of participants No placebo or comparator arm | 94.6% (n=223)e,f,g,b NCT02397096 · Phase 3 · registry result, not featured evidence show 3 more doses94.6% (n=223) @ 24wk NCT02397096 · Phase 3 · registry result, not featured evidence 90.8% (n=447) NCT02397096 · Phase 3 · registry result, not featured evidence 93.7% (n=447) @ 24wk NCT02397096 · Phase 3 · registry result, not featured evidence | 90.6% (n=32) @ 96wkf,g,b NCT00939874 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 83.6%h NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results22.2% NCT02477527 · Phase 4 · registry result, not featured evidence —DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 6.3%Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 5.1%Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence 5.1%E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 20%E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 5.4% NCT02616783 · Phase 3 · registry result, not featured evidence —Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 16%E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 43.2% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 12.3%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 12.1%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 10.2% NCT01475838 · Phase 3 · registry result, not featured evidence —All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 8.9%Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 80.7% NCT01106586 · Phase 3 · registry result, not featured evidence 0% NCT01533259 · Phase 3 · registry result, not featured evidence 14% NCT01721109 · Phase 2/3 · registry result, not featured evidence 5.3% NCT01497899 · Phase 2 · registry result, not featured evidence 6.3% NCT00869557 · Phase 2 · registry result, not featured evidence | 23.7%400 mg b.i.d.i NCT00293254 · Phase 3 · combination show 27 more results—400 mg b.i.d. NCT00293254 · Phase 3 · combination —400 mg b.i.d NCT00293267 · Phase 3 · combination 17.5%400 mg b.i.d NCT00293267 · Phase 3 · combination 25.5%400 mg b.i.d. NCT00369941 · Phase 3 15.4% NCT01147107 · Phase 4 · registry result, not featured evidence 9.5% NCT03374358 · Phase 4 · registry result, not featured evidence 0% NCT03667547 · Phase 4 · registry result, not featured evidence —Arm A Raltegravir NCT03205566 · Phase 4 · registry result, not featured evidence —Arm B Raltegravir Lamivudine NCT03205566 · Phase 4 · registry result, not featured evidence · combination 10.5% NCT02383355 · Phase 4 · registry result, not featured evidence 38.5% NCT00939874 · Phase 4 · registry result, not featured evidence 0% NCT00843713 · Phase 4 · registry result, not featured evidence 22.2% NCT01332227 · Phase 4 · registry result, not featured evidence · combination 27.3% NCT00870363 · Phase 4 · registry result, not featured evidence · combination 6.7%Switch to Tenofovir/Emtricitabine NCT01270802 · Phase 4 · registry result, not featured evidence · combination —Switch to Tenofovir/Emtricitabine/ NCT01270802 · Phase 4 · registry result, not featured evidence 35.7% NCT00762892 · Phase 4 · registry result, not featured evidence 0% NCT01335620 · Phase 4 · registry result, not featured evidence · combination 6.7%Intervention Arm No.1 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 28.6%Intervention Arm No.2 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 0%Hyper-immune Bovine Colostrum NCT00772590 · Phase 4 · registry result, not featured evidence 0%Raltegravir + Hyper-immune Bovine NCT00772590 · Phase 4 · registry result, not featured evidence · combination 0% NCT00631449 · Phase 4 · registry result, not featured evidence 7.5%1200 mg QD NCT03029689 · Phase 3 · registry result, not featured evidence · combination 4.1% NCT02284035 · Phase 3 · registry result, not featured evidence · combination —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 12.4%Reformulated Raltegravir NCT02131233 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 2.5%h NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results— NCT02477527 · Phase 4 · registry result, not featured evidence —DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 0.4%Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 1.6%Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence 0.7%E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 0.7%E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 0.9% NCT02616783 · Phase 3 · registry result, not featured evidence —Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0.9%E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 2.2% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 4.1%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 6.1%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 2% NCT01475838 · Phase 3 · registry result, not featured evidence —All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 0.7%Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 2.5% NCT01106586 · Phase 3 · registry result, not featured evidence — NCT01533259 · Phase 3 · registry result, not featured evidence — NCT01721109 · Phase 2/3 · registry result, not featured evidence 0.9% NCT01497899 · Phase 2 · registry result, not featured evidence — NCT00869557 · Phase 2 · registry result, not featured evidence | 0.9%400 mg b.i.d.i NCT00293254 · Phase 3 · combination show 27 more results—400 mg b.i.d. NCT00293254 · Phase 3 · combination —400 mg b.i.d NCT00293267 · Phase 3 · combination 0.4%400 mg b.i.d NCT00293267 · Phase 3 · combination 5%400 mg b.i.d. NCT00369941 · Phase 3 — NCT01147107 · Phase 4 · registry result, not featured evidence — NCT03374358 · Phase 4 · registry result, not featured evidence — NCT03667547 · Phase 4 · registry result, not featured evidence —Arm A Raltegravir NCT03205566 · Phase 4 · registry result, not featured evidence —Arm B Raltegravir Lamivudine NCT03205566 · Phase 4 · registry result, not featured evidence · combination 10.5% NCT02383355 · Phase 4 · registry result, not featured evidence — NCT00939874 · Phase 4 · registry result, not featured evidence — NCT00843713 · Phase 4 · registry result, not featured evidence 5.6% NCT01332227 · Phase 4 · registry result, not featured evidence · combination — NCT00870363 · Phase 4 · registry result, not featured evidence · combination 0%Switch to Tenofovir/Emtricitabine NCT01270802 · Phase 4 · registry result, not featured evidence · combination —Switch to Tenofovir/Emtricitabine/ NCT01270802 · Phase 4 · registry result, not featured evidence — NCT00762892 · Phase 4 · registry result, not featured evidence — NCT01335620 · Phase 4 · registry result, not featured evidence · combination 0%Intervention Arm No.1 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 7.1%Intervention Arm No.2 NCT00931801 · Phase 4 · registry result, not featured evidence · combination —Hyper-immune Bovine Colostrum NCT00772590 · Phase 4 · registry result, not featured evidence —Raltegravir + Hyper-immune Bovine NCT00772590 · Phase 4 · registry result, not featured evidence · combination — NCT00631449 · Phase 4 · registry result, not featured evidence —1200 mg QD NCT03029689 · Phase 3 · registry result, not featured evidence · combination — NCT02284035 · Phase 3 · registry result, not featured evidence · combination —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 1.3%Reformulated Raltegravir NCT02131233 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 19.8%h NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results0% NCT02477527 · Phase 4 · registry result, not featured evidence 1.9%DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence 6.4%DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence 4.5%DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence 2.3%DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence —Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence 2.9%ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence 2.6%ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence 9.3%ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence 4.3%ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence 3.6%ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence —Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence —E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 3%Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence 5.2%Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence 8.2%Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence 12.5%E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence 2.8%Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence 1.7%Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence 5.3%DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence 8.7%Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 9.1% NCT02616783 · Phase 3 · registry result, not featured evidence 16.8%Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 20.6% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 15.1%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 18.2%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 8.2% NCT01475838 · Phase 3 · registry result, not featured evidence 8.9%All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 8.2%Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 16.4% NCT01106586 · Phase 3 · registry result, not featured evidence 2.1% NCT01533259 · Phase 3 · registry result, not featured evidence 10% NCT01721109 · Phase 2/3 · registry result, not featured evidence 10.7% NCT01497899 · Phase 2 · registry result, not featured evidence 4.2% NCT00869557 · Phase 2 · registry result, not featured evidence | —400 mg b.i.d.i NCT00293254 · Phase 3 · combination show 27 more results34.8%400 mg b.i.d. NCT00293254 · Phase 3 · combination 41.8%400 mg b.i.d NCT00293267 · Phase 3 · combination —400 mg b.i.d NCT00293267 · Phase 3 · combination 20.3%400 mg b.i.d. NCT00369941 · Phase 3 21.1% NCT01147107 · Phase 4 · registry result, not featured evidence 0% NCT03374358 · Phase 4 · registry result, not featured evidence 0% NCT03667547 · Phase 4 · registry result, not featured evidence 0%Arm A Raltegravir NCT03205566 · Phase 4 · registry result, not featured evidence 0%Arm B Raltegravir Lamivudine NCT03205566 · Phase 4 · registry result, not featured evidence · combination 0% NCT02383355 · Phase 4 · registry result, not featured evidence 13.5% NCT00939874 · Phase 4 · registry result, not featured evidence 3.8% NCT00843713 · Phase 4 · registry result, not featured evidence 5.6% NCT01332227 · Phase 4 · registry result, not featured evidence · combination 0% NCT00870363 · Phase 4 · registry result, not featured evidence · combination —Switch to Tenofovir/Emtricitabine NCT01270802 · Phase 4 · registry result, not featured evidence · combination 0%Switch to Tenofovir/Emtricitabine/ NCT01270802 · Phase 4 · registry result, not featured evidence 7.1% NCT00762892 · Phase 4 · registry result, not featured evidence 0% NCT01335620 · Phase 4 · registry result, not featured evidence · combination 13.3%Intervention Arm No.1 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 14.3%Intervention Arm No.2 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 0%Hyper-immune Bovine Colostrum NCT00772590 · Phase 4 · registry result, not featured evidence 5.3%Raltegravir + Hyper-immune Bovine NCT00772590 · Phase 4 · registry result, not featured evidence · combination 0% NCT00631449 · Phase 4 · registry result, not featured evidence 0%1200 mg QD NCT03029689 · Phase 3 · registry result, not featured evidence · combination 6.1% NCT02284035 · Phase 3 · registry result, not featured evidence · combination 9.6%1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination —Reformulated Raltegravir NCT02131233 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | h diarrhoea 26.7% upper respiratory tract infection 26.4% nausea 23% NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 31 more resultsheadache 6.7% diarrhoea 4.3% nasopharyngitis 4.3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.4% headache 6.4% diarrhoea 5.4% NCT02397096 · Phase 3 · registry result, not featured evidence covid-19 3.9% headache 1.9% back pain 1.3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.4% headache 6.5% diarrhoea 4.5% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.4% back pain 3.7% diarrhoea 3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 12.8% headache 5.5% arthralgia 5.3% NCT02397096 · Phase 3 · registry result, not featured evidence back pain 2.3% arthralgia 1.7% nasopharyngitis 1.7% NCT02397096 · Phase 3 · registry result, not featured evidence covid-19 8.3% arthralgia 1.2% diarrhoea 1.2% NCT02397096 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 7.4% nasopharyngitis 5.2% diarrhoea 4.4% NCT01815736 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 6.1% diarrhoea 5.2% nasopharyngitis 4.7% NCT01815736 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.5% diarrhoea 11.4% nasopharyngitis 10% NCT01815736 · Phase 3 · registry result, not featured evidence diarrhoea 23% headache 22.7% upper respiratory tract infection 20.2% NCT01797445 · Phase 3 · registry result, not featured evidence nasopharyngitis 3.5% headache 2.8% arthralgia 1.4% NCT01797445 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.2% cough 2.5% syphilis 2.5% NCT01797445 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 14.6% headache 11% anaemia 7.3% NCT01705574 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.3% headache 17% nausea 14.9% NCT01705574 · Phase 3 · registry result, not featured evidence nasopharyngitis 10.9% back pain 8.2% diarrhoea 7.3% NCT02616783 · Phase 3 · registry result, not featured evidence diarrhoea 25.7% upper respiratory tract infection 21.1% nausea 16.8% NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 cough 4.4% syphilis 4.4% upper respiratory tract infection 3.3% NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 diarrhoea 33.9% upper respiratory tract infection 21.2% headache 13.8% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 upper respiratory tract infection 20.5% nasopharyngitis 19.2% bronchitis 13.7% NCT01363011 · Phase 3 · registry result, not featured evidence · combination diarrhoea 36.4% insomnia 21.2% headache 18.2% NCT01363011 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 13.3% upper respiratory tract infection 9.9% diarrhoea 9.2% NCT01475838 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 11.3% diarrhoea 10.2% nasopharyngitis 10.2% NCT01495702 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 11.3% diarrhoea 10.3% nasopharyngitis 10.3% NCT01495702 · Phase 3 · registry result, not featured evidence diarrhoea 28% upper respiratory tract infection 24.4% nausea 22.7% NCT01106586 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 20.8% insomnia 12.5% anxiety 10.4% NCT01533259 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 36% headache 24% vomiting 20% NCT01721109 · Phase 2/3 · registry result, not featured evidence nausea 22.3% diarrhoea 17% fatigue 16.1% NCT01497899 · Phase 2 · registry result, not featured evidence diarrhoea 27.1% fatigue 16.7% headache 14.6% NCT00869557 · Phase 2 · registry result, not featured evidence | 400 mg b.i.d.i upper respiratory tract infection 33% (placebo 24.4%) diarrhoea 32.6% (placebo 29.4%) fatigue 19.6% (placebo 15.1%) NCT00293254 · Phase 3 · combination show 17 more results400 mg b.i.d diarrhoea 31.9% (placebo 28.8%) nasopharyngitis 25% (placebo 17.8%) bronchitis 18.1% (placebo 13.6%) NCT00293267 · Phase 3 · combination alt elevation 55.3% NCT01147107 · Phase 4 · registry result, not featured evidence sleeping difficulties 52.6% (placebo 54.2%) gastrointestinal (diarrhoea, nausea) 47.4% (placebo 29.2%) headache 47.4% (placebo 33.3%) NCT03374358 · Phase 4 · registry result, not featured evidence runny nose 10.5% cold 5.3% diarrhoea 5.3% NCT03205566 · Phase 4 · registry result, not featured evidence nightmares and vivid dreams 13.2% diarrhoea 7.9% headache 7.9% NCT03205566 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 18.9% diarrhoea 10.8% abdominal cramps 5.4% NCT00939874 · Phase 4 · registry result, not featured evidence hyperbilirubinemia 3.8% (placebo 0%) NCT00843713 · Phase 4 · registry result, not featured evidence hyperbilirubinaemia 8.3% ocular icterus 8.3% bronchitis 5.6% NCT01332227 · Phase 4 · registry result, not featured evidence · combination gastrointestinal intolerance 9.1% neuropsychiatric side effect 0% NCT00870363 · Phase 4 · registry result, not featured evidence · combination neutropenia 6.7% diastolic hypertension 0% impaired fasting glucose 0% NCT01270802 · Phase 4 · registry result, not featured evidence bronchitis 20% diarrhea 20% headache 20% NCT00931801 · Phase 4 · registry result, not featured evidence · combination diarrhea 21.4% upper respiratory infection 21.4% fatigue 14.3% NCT00931801 · Phase 4 · registry result, not featured evidence · combination 1200 mg QD adverse event not related to the treatment 2.6% (placebo 5.6%) NCT03029689 · Phase 3 · registry result, not featured evidence · combination insomnia 8.2% amigdalitis 6.1% common cold 6.1% NCT02284035 · Phase 3 · registry result, not featured evidence · combination 1200 mg QD + Truvada headache 15.8% nausea 13.6% diarrhoea 13.4% NCT02131233 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dTrial phases differ: Phase 2/3 versus Phase 3.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fTrial phases differ: Phase 3 versus Phase 4.
- gPopulation context differs: registered conditions differ.
- hPopulation comparability has not been reviewed for 34 of these studies.
- iPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Elvitegravir
show 34 more results
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 5 more results
show 11 more results
show 1 more result
show 1 more result
+ 10 further endpoints in the CSV export.
Raltegravir
show 5 more results
show 1 more result
show 5 more results
show 1 more result
show 6 more results
show 1 more result
show 7 more results
show 3 more results
+ 17 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elvitegravir's landscape · Raltegravir's landscape